keyword
Keywords Bisphosphonate use in children...

Bisphosphonate use in children with leukemia

https://read.qxmd.com/read/36518777/malignant-hypercalcemia-as-the-debut-of-acute-lymphoblastic-leukemia-in-a-pediatric-patient-a-diagnostic-and-therapeutic-approach-case-report
#1
Carolina Bonilla Gonzalez, Sarha M Vargas Muñoz, María Luisa Contreras Diaz, Evelyn Obando Belalcazar, Camila Uribe
BACKGROUND: Hypercalcemia is a rare metabolic disorder in the pediatric population, with several differential diagnoses that resemble hematologic malignancies. In cases of severe hypercalcemia, therapeutic strategies other than hyperhydration, such as the use of bisphosphonates, have been described. CASE PRESENTATION: We present the case of a previously healthy 12-year-old boy who was admitted to the emergency department due to fatigue, hypo-responsiveness, and progressively worsening poor appetite for the previous 19 days...
2022: Frontiers in Pediatrics
https://read.qxmd.com/read/36472650/osteoporosis-in-children-and-adolescents-how-to-treat-and-monitor
#2
REVIEW
Silvia Ciancia, Wolfgang Högler, Ralph J B Sakkers, Natasha M Appelman-Dijkstra, Annemieke M Boot, Theo C J Sas, Judith S Renes
UNLABELLED: Osteoporosis is a condition of increased bone fragility associated with fractures. Apart from primary genetic osteoporotic conditions, secondary osteoporosis in children is being increasingly recognized. As a result, there is growing interest in its prevention and treatment. Important goals of care are to prevent fractures, increase bone mass and trabecular and cortical thickness, reshape vertebral fractures, prevent (or correct) skeletal deformities, and improve mobility, independence, and quality of life...
February 2023: European Journal of Pediatrics
https://read.qxmd.com/read/34309491/bisphosphonate-treatment-in-children-with-acute-lymphoblastic-leukemia-and-osteonecrosis-radiological-and-clinical-findings-in-a-national-cohort
#3
JOURNAL ARTICLE
Pauliina Utriainen, Tuukka T Niinimäki, Anu J Huurre, Kaisa L Vepsäläinen, Outi M Mäkitie, Riitta A Niinimäki
Background: Osteonecrosis (ON) is a recognized complication of childhood ALL, but its optimal management remains unestablished. This study evaluated the effect of bisphosphonate (BP) treatment on the evolution of ON lesions in childhood ALL. Material and Methods: We included a national cohort of ALL patients diagnosed with symptomatic ON before 18 years of age and treated with BPs ( N  = 10; five males). Patients were followed both clinically and with serial MRIs. ON lesions were graded according to the Niinimäki classification...
September 2021: Acta Oncologica
https://read.qxmd.com/read/33128074/methotrexate-osteopathy-five-cases-and-systematic-literature-review
#4
REVIEW
F Robin, S Cadiou, J-D Albert, G Bart, G Coiffier, P Guggenbuhl
INTRODUCTION: Methotrexate (MTX)-related osteopathy is rare, defined by the triad of pain, osteoporosis, and "atypical fractures" when it was first described in the 1970s in children treated with high doses MTX for acute leukemia. Since then, several cases have been reported in patients treated with low-dose MTX for inflammatory diseases. METHODS: A systematic research of cases of MTX-related osteopathy was performed in records of Rheumatology Department of Rennes University Hospital...
October 30, 2020: Osteoporosis International
https://read.qxmd.com/read/32324697/bisphosphonate-therapy-for-treating-osteonecrosis-in-pediatric-leukemia-patients-a-systematic-review
#5
JOURNAL ARTICLE
Shanaz M Daneshdoost, Jad M El Abiad, Kathy J Ruble, Lynne C Jones, Janet L Crane, Carol D Morris, Adam S Levin
BACKGROUND: Despite improved outcomes in children with leukemia, complications such as osteonecrosis are common. We conducted a systematic review to investigate the role of bisphosphonates in reducing pain, improving mobility, and stabilizing lesions in pediatric leukemia survivors. METHODS: Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we searched the PubMed, Embase, Cochrane, Web of Science, Scopus, CINAHL, and ClinicalTrials...
April 1, 2021: Journal of Pediatric Hematology/oncology
https://read.qxmd.com/read/26907650/severe-hypercalcemia-in-a-child-with-acute-lymphoblastic-leukemia-relapse-successful-management-with-combination-of-calcitonin-and-bisphosphonate
#6
JOURNAL ARTICLE
Anar Tagiyev, Huseyin Demirbilek, Betul Tavil, Gonul Buyukyilmaz, Fatma Gumruk, Mualla Cetin
Hypercalcemia is a rare complication of hematological malignancy in children. An 8-year-old girl with CALLA (+) Pre-B-cell ALL developed hypercalcemia during bone marrow relapse. She had nausea, vomiting, leg pain, polyuria, polydipsia, and muscle weakness. At the time of relapse, the ionized calcium level was 1.99 mmol/L. Rehydration with 0.9% saline and furosemide and methylprednisolone (MP) treatment were used for the treatment of hypercalcemia. The serum ionized calcium level increased to 2.2 mmol/L despite hydration, furosemide, and MP treatment...
April 2016: Journal of Pediatric Hematology/oncology
https://read.qxmd.com/read/24598854/management-and-treatment-of-osteonecrosis-in-children-and-adolescents-with-acute-lymphoblastic-leukemia
#7
REVIEW
Mariël L Te Winkel, Rob Pieters, Ernst-Jan D Wind, J H J M Gert Bessems, Marry M van den Heuvel-Eibrink
There is no consensus regarding how to manage osteonecrosis in pediatric acute lymphoblastic leukemia patients. Therefore, we performed a quality assessment of the literature with the result of a search strategy using the MESH terms osteonecrosis, children, childhood cancer, surgery, bisphosphonates, 6 hydroxymethyl-glutaryl CoA reductase inhibitors, anticoagulants and hyperbaric oxygen, and terms related to these MESH terms. A randomized controlled trial showed that osteonecrosis can be prevented by intermittent, instead of continuous, corticosteroid administration...
March 2014: Haematologica
https://read.qxmd.com/read/23826578/efficacy-of-pamidronate-in-children-with-low-bone-mineral-density-during-and-after-chemotherapy-for-acute-lymphoblastic-leukemia-and-non-hodgkin-lymphoma
#8
JOURNAL ARTICLE
Jae Min Lee, Ji Eun Kim, Soon Hwan Bae, Jeong Ok Hah
BACKGROUND: Reduced bone mineral density (BMD) is a significant sequelae in children receiving chemotherapy for acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). Reduced BMD is associated with an increased risk for fractures. Pamidronate, a second-generation bisphosphonate, has been used to treat osteoporosis in children. This study evaluated the safety and efficacy of pamidronate in children with low BMD during and after chemotherapy for ALL and NHL. METHODS: Between April 2007 and October 2011, 24 children with ALL and NHL were treated with pamidronate...
June 2013: Blood Research
https://read.qxmd.com/read/19336653/treatment-of-osteoporosis-osteopenia-in-pediatric-leukemia-and-lymphoma
#9
REVIEW
Michele L Bryant, Mary A Worthington, Kerry Parsons
OBJECTIVE: To evaluate the efficacy and safety of various treatment options for osteopenia and osteoporosis secondary to cancer treatment in pediatric patients undergoing cancer therapy. DATA SOURCES: A systematic search of PubMed (1949-November 2008) and International Pharmaceutical Abstracts (to November 2008) was conducted using the following search terms: osteoporosis, osteopenia, pediatrics, cancer, neoplasms, chemotherapy, bisphosphonates, calcium, vitamin D, calcitonin, and physical therapy...
April 2009: Annals of Pharmacotherapy
https://read.qxmd.com/read/17805035/bisphosphonate-therapy-for-reduced-bone-mineral-density-during-treatment-of-acute-lymphoblastic-leukemia-in-childhood-and-adolescence-a-report-of-preliminary-experience
#10
JOURNAL ARTICLE
Christopher Lethaby, John Wiernikowski, Alessandra Sala, Marissa Naronha, Colin Webber, Ronald D Barr
BACKGROUND: Osteopenia is a common consequence of the treatment of acute lymphoblastic leukemia (ALL) in children and adolescents, due predominantly to glucocorticosteroid therapy. The pathogenesis relates to an imbalance of resorption over formation of bone. METHODS: Alendronate (Fosamax), an inhibitor of osteoclastic bone resorption, was administered for at least 6 months to 15 children with ALL during maintenance chemotherapy, after the diagnosis of osteopenia/osteoporosis by dual energy x-ray absorptiometry...
September 2007: Journal of Pediatric Hematology/oncology
https://read.qxmd.com/read/17172070/use-of-bisphosphonates-for-resistant-hypercalcemia-in-children-with-acute-lymphoblastic-leukemia-report-of-two-cases-and-review-of-the-literature
#11
REVIEW
Nesibe Andiran, Ayfer Alikaşifoğlu, Serhan Küpeli, Sevgi Yetgin
Hypercalcemia is a rare complication of malignancy in children. We present two children, one of whom is the youngest reported, with CALLA+ B-cell acute lymphoblastic leukemia (ALL) who developed hypercalcemia at the time of diagnosis and were treated with relatively low-dose (0.5 mg/kg) intravenous pamidronate successive to conventional therapy. No major side effects were encountered except transient hypocalcemia and hypophosphatemia, which were easily managed by replacement therapy. Bisphosphonate therapy was found to be beneficial for the treatment of resistant hypercalcemia associated with ALL, even at relatively low doses...
July 2006: Turkish Journal of Pediatrics
https://read.qxmd.com/read/11225473/pamidronate-and-calcitonin-as-therapy-of-acute-cancer-related-hypercalcemia-in-children
#12
COMPARATIVE STUDY
I Schmid, D Stachel, C Schön, M Bauer, R J Haas
Severe symptomatic hypercalcemia is a rare event in children with malignancies. Up to now there is limited experience treating childhood hypercalcemia with bisphosphonates in addition to calcitonin. We report a 5-year-old boy with acute lymphoblastic lymphoma who presented with malignant hypercalcemia at diagnosis. The maximal serum calcium concentration was 15.2 mg/dl (3.81 mmol/l). Conventional therapy with forced diuresis and furosemide failed. Calcitonin (10 IU/kg/24 h i.v. for 2 days) and pamidronate (1 mg/kg over 2 hours i...
January 2001: Klinische Pädiatrie
https://read.qxmd.com/read/9755274/bisphosphonates-for-treatment-of-childhood-hypercalcemia
#13
REVIEW
A N Lteif, D Zimmerman
Most clinicians only have a limited experience in treating childhood hypercalcemia with bisphosphonates. We report our experience in the use of intravenous and oral bisphosphonates in a 5-year-old with hypercalcemia secondary to acute lymphocytic leukemia, a 16-year-old with immobilization hypercalcemia, and a 14-year-old with chronic hypercalcemia of unknown cause. Single infusions of 0.5 mg/kg and 1 mg/kg of intravenous pamidronate were administered over 4 hours. No adverse reactions were observed except for hypocalcemia...
October 1998: Pediatrics
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.